• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

糖尿病心肌病发病机制的基础。

The Pathophysiological Basis of Diabetic Cardiomyopathy Development.

机构信息

Pathological Anatomy and Clinical Morphology Department, Yerevan State Medical University after M. Heratsi, Yerevan, Republic of Armenia.

Director of Cardiology Research Institute of Tomsk National Research Medical Center of Russian Academy of Sciences, Tomsk, Russia.

出版信息

Curr Probl Cardiol. 2022 Sep;47(9):101156. doi: 10.1016/j.cpcardiol.2022.101156. Epub 2022 Feb 19.

DOI:10.1016/j.cpcardiol.2022.101156
PMID:35192869
Abstract

Diabetes mellitus (DM) provokes widely known structural and functional dyscoordination of the myocardium performance. A cascade of pathophysiological changes occurs due to metabolic disorders caused by hyperglycemia, insulin resistance, and dyslipidemia. Free fatty acids can stimulate oxidation and accumulate in the cytosol, leading to lipotoxic effects by forming ceramides, diacylglycerol, and reactive oxygen species (ROS). Hyperglycemia also causes an increase in the content of reactive oxygen species and the formation of advanced glycation end (AGE) products, which is accompanied by the development of cardiac glucotoxicity. The combination of these pathophysiological processes, ATP deficiency, and the development of myocardial fatty degeneration induce calcium stress, as well as dysfunction of mitochondria and endoplasmic reticulum, activation of signaling pathways of protein kinase C (PKC), mitogen-activated protein kinases (MAPK), etc., causing chronic sluggish inflammation, as well as first diastolic and further systolic dysfunction, and myocardial fibrosis. This article reviews the data on diabetic alteration of the cardiovascular system.

摘要

糖尿病(DM)引起心肌功能的广泛而熟知的结构和功能失调。由于高血糖、胰岛素抵抗和血脂异常引起的代谢紊乱,会引发一连串的病理生理变化。游离脂肪酸可以刺激氧化并在细胞质中积累,通过形成神经酰胺、二酰基甘油和活性氧物质(ROS)而导致脂毒性作用。高血糖还会导致活性氧物质含量增加和晚期糖基化终末产物(AGE)的形成,这伴随着心脏糖毒性的发展。这些病理生理过程、ATP 缺乏以及心肌脂肪变性的发展会导致钙应激,以及线粒体和内质网功能障碍、蛋白激酶 C(PKC)、丝裂原活化蛋白激酶(MAPK)等信号通路的激活,导致慢性迟钝性炎症,以及最初的舒张功能障碍和进一步的收缩功能障碍,以及心肌纤维化。本文综述了关于糖尿病对心血管系统影响的相关数据。

相似文献

1
The Pathophysiological Basis of Diabetic Cardiomyopathy Development.糖尿病心肌病发病机制的基础。
Curr Probl Cardiol. 2022 Sep;47(9):101156. doi: 10.1016/j.cpcardiol.2022.101156. Epub 2022 Feb 19.
2
Molecular Dysfunction and Phenotypic Derangement in Diabetic Cardiomyopathy.糖尿病心肌病中的分子功能障碍和表型紊乱。
Int J Mol Sci. 2019 Jul 2;20(13):3264. doi: 10.3390/ijms20133264.
3
Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity.糖尿病性心肌病:导致这一临床实体的机制更新。
Circ Res. 2018 Feb 16;122(4):624-638. doi: 10.1161/CIRCRESAHA.117.311586.
4
Endothelial Dysfunction and Diabetic Cardiomyopathy.内皮功能障碍与糖尿病心肌病。
Front Endocrinol (Lausanne). 2022 Apr 7;13:851941. doi: 10.3389/fendo.2022.851941. eCollection 2022.
5
Cannabinoid 1 receptor promotes cardiac dysfunction, oxidative stress, inflammation, and fibrosis in diabetic cardiomyopathy.大麻素 1 型受体促进糖尿病心肌病中心功能障碍、氧化应激、炎症和纤维化。
Diabetes. 2012 Mar;61(3):716-27. doi: 10.2337/db11-0477. Epub 2012 Feb 7.
6
A correlation between oxidative stress and diabetic retinopathy: An updated review.氧化应激与糖尿病视网膜病变的相关性:最新综述。
Exp Eye Res. 2023 Nov;236:109650. doi: 10.1016/j.exer.2023.109650. Epub 2023 Sep 19.
7
Diabetic cardiomyopathy and inflammation: development of hostile microenvironment resulting in cardiac damage.糖尿病性心肌病与炎症:敌对微环境的发展导致心脏损伤。
Minerva Cardiol Angiol. 2022 Jun;70(3):357-369. doi: 10.23736/S2724-5683.20.05454-7. Epub 2021 Jan 11.
8
Diabetic Cardiomyopathy: 2023 Update by the International Multidisciplinary Board of Experts.糖尿病性心肌病:国际多学科专家委员会2023年更新版
Curr Probl Cardiol. 2024 Jan;49(1 Pt A):102052. doi: 10.1016/j.cpcardiol.2023.102052. Epub 2023 Aug 26.
9
Cardiac oxidative stress in diabetes: Mechanisms and therapeutic potential.糖尿病患者的心脏氧化应激:机制与治疗潜力。
Pharmacol Ther. 2017 Apr;172:50-62. doi: 10.1016/j.pharmthera.2016.11.013. Epub 2016 Dec 1.
10
Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment.糖尿病性心肌病:从分子和细胞基础理解以促进诊断和治疗。
Heart Fail Rev. 2012 May;17(3):325-44. doi: 10.1007/s10741-011-9257-z.

引用本文的文献

1
Exploration of serum biomarkers in heart failure patients with preserved and reduced ejection fractions through analysis of heterogeneity.通过异质性分析探索射血分数保留和降低的心力衰竭患者的血清生物标志物
Biochem Biophys Rep. 2025 Jul 31;43:102183. doi: 10.1016/j.bbrep.2025.102183. eCollection 2025 Sep.
2
Global research trends in the relationship between diabetic cardiomyopathy and mitochondria: a bibliometric analysis.糖尿病性心肌病与线粒体关系的全球研究趋势:一项文献计量分析
Hereditas. 2025 Jul 1;162(1):114. doi: 10.1186/s41065-025-00488-3.
3
Antioxidant proteins can be potential targets in ameliorating ferroptosis in diabetic cardiomyopathy: a literature review.
抗氧化蛋白可能是改善糖尿病性心肌病中铁死亡的潜在靶点:一项文献综述。
Diabetol Metab Syndr. 2025 Jun 7;17(1):199. doi: 10.1186/s13098-025-01773-x.
4
ERK1/2 gene expression and hypomethylation of Alu and LINE1 elements in patients with type 2 diabetes with and without cataract: Impact of hyperglycemia-induced oxidative stress.2型糖尿病合并或不合并白内障患者中ERK1/2基因表达以及Alu和LINE1元件的低甲基化:高血糖诱导的氧化应激的影响
J Diabetes Investig. 2025 Apr;16(4):689-706. doi: 10.1111/jdi.14405. Epub 2025 Jan 13.
5
The protective effects of liraglutide in reducing lipid droplets accumulation and myocardial fibrosis in diabetic cardiomyopathy.利拉鲁肽在减少糖尿病性心肌病中脂滴积累和心肌纤维化方面的保护作用。
Cell Mol Life Sci. 2025 Jan 8;82(1):39. doi: 10.1007/s00018-024-05558-9.
6
Diabetic Cardiomyopathy: An Update on Emerging Pathological Mechanisms.糖尿病性心肌病:新兴病理机制的最新进展
Curr Cardiol Rev. 2025;21(2):88-107. doi: 10.2174/011573403X331870241025094307.
7
Repair and regeneration: ferroptosis in the process of remodeling and fibrosis in impaired organs.修复与再生:受损器官重塑和纤维化过程中的铁死亡
Cell Death Discov. 2024 Oct 2;10(1):424. doi: 10.1038/s41420-024-02181-2.
8
Role of bariatric surgery in improving diabetic cardiomyopathy: Molecular mechanisms and therapeutic perspectives (Review).减重手术改善糖尿病性心肌病的作用:分子机制和治疗观点(综述)。
Mol Med Rep. 2024 Nov;30(5). doi: 10.3892/mmr.2024.13323. Epub 2024 Sep 6.
9
Selective aldose reductase inhibition as a treatment for diabetic cardiomyopathy: summary of the ARISE-HF trial.选择性醛糖还原酶抑制作为糖尿病性心肌病的一种治疗方法:ARISE-HF试验总结
Heart Fail Rev. 2024 Sep;29(5):1157-1160. doi: 10.1007/s10741-024-10427-5. Epub 2024 Jul 25.
10
Diabetes cardiomyopathy: targeted regulation of mitochondrial dysfunction and therapeutic potential of plant secondary metabolites.糖尿病心肌病:线粒体功能障碍的靶向调控及植物次生代谢产物的治疗潜力
Front Pharmacol. 2024 Jul 9;15:1401961. doi: 10.3389/fphar.2024.1401961. eCollection 2024.